Printer Friendly

HYAL PHARMACEUTICAL CORPORATION

HYAL PHARMACEUTICAL CORPORATION
 TORONTO, Oct. 2 /CNW/ - In response to recent fluctuations in the price of the Company's stock, Dr. Samuel Asculai, President of Hyal Pharmaceutical Corporation, reported that he was unaware of any reason for these fluctuations and that, in fact, the Company is on track with its product development plans. He further advised that the Company has commenced its Phase III clinical trials for the treatment of basal cell carcinoma and continues with its Phase III clinical trials for the topical treatment of pain.
 In June of this year the Company completed an offering of common shares and warrants for net proceeds of $11,700,000, which complimented an equity issue in the fall of 1991 which provided net proceeds of $8,600,000. As a result of these financings, the Company has a strong balance sheet and possesses the financial resources to fund its ongoing development programs.
 Hyal is a Canadian company dedicated to the development and commercialization of pharmaceutical formulations utilizing its Hyaluronic Acid-based delivery technology.
 For further information: Dr. Samuel S. Asculai, President & C.E.O., (416) 366-4863 or Mr. Michael A. Byrne, Vice President Finance, (416) 678-6800
 (HPC.)
 -0- 10/02/92


CO: HYAL PHARMACEUTICAL CORPORATION IN: MTC ST: -- c0323 -- X127 10/02/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 2, 1992
Words:210
Previous Article:THE ONDAATJE CORPORATION (FORMERLY LOWEN, ONDAATJE, MCCUTCHEON INC.) CANACCORD CAPITAL CORPORATION
Next Article:UNITED NURSES OF ALBERTA VOTE IN FAVOUR
Topics:


Related Articles
HYAL PHARMACEUTICAL NASDAQ LISTING EFFECTIVE
HYAL'S NEW AND UNEXPECTED MECHANISM FOR PAIN RELIEF
DRUGS TARGETED TO CANCER TUMORS BY HYAL'S DRUG DELIVERY TECHNOLOGY
HYAL'S TOPICAL PAIN FORMULATION EFFECTIVE IN TREATING INTRACTABLE PAIN
ADDITIONAL INFORMATION ON AUSTRIAN TOPICAL PAIN TRIALS
HYAL PHARMACEUTICAL AUSTRALIA LIMITED LISTS ON THE AUSTRALIAN STOCK EXCHANGE
HYAL'S AUSTRALIAN SUBSIDIARY PROCEEDS WITH $10 MILLION FUND RAISING
HYAL COMPLETES US$8 MILLION PRIVATE PLACEMENT
Hyal Successfully Restructures Debentures
Solarase(TM) Approved in Germany, Sweden, France and Italy

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters